Added to YB: 2026-03-06
Pitch date: 2026-03-05
IBRX [neutral]
ImmunityBio, Inc.
Author Info
Company Info
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
Market Cap
$10.3B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-49.02
P/E
-26.18
EV/Sales
96.07
Sector
Biotechnology
Category
growth
Immunity Bio: The Platform Begins.
IBRX (holding update): IL-15 superagonist Anktiva boosts NK/T cells for immune rejuvenation. Q4 rev +700% YoY, 750% unit volume growth. Now approved in 33 countries (US, EU, UK, Saudi). Platform layers: NaNT (allogeneic NK cells), DNA vaccine (antigen targeting), CAR-NK, PD-L1 NK. FDA's new 'plausible mechanism' pathway accelerates approvals across indications without 150 trials for 150 mutations. Positions as immune system API for personalized pathogen/tumor clearance.
Read full article (6 min)